EP0810853B1
(en)
|
1995-02-24 |
2004-08-25 |
Elan Pharma International Limited |
Aerosols containing nanoparticle dispersions
|
IT1277376B1
(it)
*
|
1995-07-28 |
1997-11-10 |
Euron Spa |
Copolimeri a blocchi loro preparazione e loro uso come lubrificanti
|
US5766629A
(en)
|
1995-08-25 |
1998-06-16 |
Sangstat Medical Corporation |
Oral cyclosporin formulations
|
US5834025A
(en)
*
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
US20050267302A1
(en)
*
|
1995-12-11 |
2005-12-01 |
G.D. Searle & Co. |
Eplerenone crystalline form exhibiting enhanced dissolution rate
|
US5993856A
(en)
*
|
1997-01-24 |
1999-11-30 |
Femmepharma |
Pharmaceutical preparations and methods for their administration
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
KR100493110B1
(ko)
*
|
1997-09-09 |
2005-09-12 |
주식회사 코오롱 |
열가소성합성섬유부직포및그의제조방법
|
US6884842B2
(en)
|
1997-10-14 |
2005-04-26 |
Alnis Biosciences, Inc. |
Molecular compounds having complementary surfaces to targets
|
UA72189C2
(uk)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US20070160675A1
(en)
*
|
1998-11-02 |
2007-07-12 |
Elan Corporation, Plc |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
MXPA01004381A
(es)
|
1998-11-02 |
2005-09-08 |
Elan Corp Plc |
Composicion de multiparticulado de liberacion modificada.
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
US6428814B1
(en)
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
US6969529B2
(en)
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
US7919119B2
(en)
*
|
1999-05-27 |
2011-04-05 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
US6610317B2
(en)
|
1999-05-27 |
2003-08-26 |
Acusphere, Inc. |
Porous paclitaxel matrices and methods of manufacture thereof
|
US6656504B1
(en)
|
1999-09-09 |
2003-12-02 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
|
NZ513960A
(en)
|
1999-12-08 |
2004-02-27 |
Pharmacia Corp |
Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
AU2041101A
(en)
*
|
1999-12-08 |
2001-06-18 |
Pharmacia Corporation |
Eplerenone crystalline form
|
US20030083493A1
(en)
*
|
1999-12-08 |
2003-05-01 |
Barton Kathleen P. |
Eplerenone drug substance having high phase purity
|
MY120279A
(en)
|
2000-05-26 |
2005-09-30 |
Pharmacia Corp |
Use of a celecoxib composition for fast pain relief
|
US6589557B2
(en)
|
2000-06-15 |
2003-07-08 |
Acusphere, Inc. |
Porous celecoxib matrices and methods of manufacture thereof
|
US6800297B2
(en)
*
|
2000-06-15 |
2004-10-05 |
Acusphere, Inc. |
Porous COX-2 inhibitor matrices and methods of manufacture thereof
|
JP2004503601A
(ja)
*
|
2000-07-13 |
2004-02-05 |
ファルマシア・コーポレーション |
眼のcox−2媒介疾患の処置及び予防におけるcox−2阻害剤の使用法
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
US7198795B2
(en)
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US6869617B2
(en)
*
|
2000-12-22 |
2005-03-22 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US20050048126A1
(en)
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US7193084B2
(en)
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
CA2451161A1
(en)
*
|
2001-06-22 |
2003-01-03 |
Elan Pharma International, Ltd. |
Method for high through put screening using a small scale mill or microfluidics
|
US7758890B2
(en)
|
2001-06-23 |
2010-07-20 |
Lyotropic Therapeutics, Inc. |
Treatment using dantrolene
|
CA2460867C
(en)
*
|
2001-09-19 |
2011-04-12 |
Elan Pharma International Ltd. |
Nanoparticulate insulin formulations
|
WO2003026662A1
(en)
*
|
2001-09-25 |
2003-04-03 |
Pharmacia Corporation |
Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
EP1429749A2
(en)
|
2001-09-26 |
2004-06-23 |
Baxter International Inc. |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
US6908626B2
(en)
|
2001-10-12 |
2005-06-21 |
Elan Pharma International Ltd. |
Compositions having a combination of immediate release and controlled release characteristics
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
WO2003039601A1
(en)
*
|
2001-11-07 |
2003-05-15 |
Imcor Pharmaceutical Company |
Methods for vascular imaging using nanoparticulate contrast agents
|
US8226972B2
(en)
|
2001-12-20 |
2012-07-24 |
Femmepharma Holding Company, Inc. |
Vaginal delivery of drugs
|
CA2475092C
(en)
|
2002-02-04 |
2012-05-01 |
Christian F. Wertz |
Nanoparticulate compositions having lysozyme as a surface stabilizer
|
WO2003082213A2
(en)
*
|
2002-03-28 |
2003-10-09 |
Imcor Pharmaceutical Company |
Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
|
US9101540B2
(en)
*
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
PT1494649E
(pt)
|
2002-04-12 |
2012-04-11 |
Alkermes Pharma Ireland Ltd |
Formulações de megestrol em nanopartículas
|
US7101576B2
(en)
*
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
ATE419835T1
(de)
*
|
2002-05-06 |
2009-01-15 |
Elan Pharma Int Ltd |
Nystatin-nanopartikelzusammensetzungen
|
US7763278B2
(en)
*
|
2002-06-10 |
2010-07-27 |
Elan Pharma International Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
JP4776229B2
(ja)
*
|
2002-07-16 |
2011-09-21 |
エラン ファーマ インターナショナル,リミティド |
安定なナノ粒子活性物質の液体投与組成物
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
US7713551B2
(en)
*
|
2002-09-11 |
2010-05-11 |
Elan Pharma International Ltd. |
Gel stabilized nanoparticulate active agent compositions
|
US20040173696A1
(en)
*
|
2002-12-17 |
2004-09-09 |
Elan Pharma International Ltd. |
Milling microgram quantities of nanoparticulate candidate compounds
|
US9173836B2
(en)
|
2003-01-02 |
2015-11-03 |
FemmeParma Holding Company, Inc. |
Pharmaceutical preparations for treatments of diseases and disorders of the breast
|
WO2004060322A2
(en)
|
2003-01-02 |
2004-07-22 |
Femmepharma Holding Company, Inc. |
Pharmaceutical preparations for treatments of diseases and disorders of the breast
|
EP1587499A1
(en)
*
|
2003-01-31 |
2005-10-26 |
Elan Pharma International Limited |
Nanoparticulate topiramate formulations
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
DE10306761B9
(de)
*
|
2003-02-17 |
2004-12-23 |
Völkl, Klaus Peter, Dr. |
Verfahren zur Herstellung von sterilen pharmazeutischen Wirkstoffen
|
US8512727B2
(en)
*
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
CA2523035C
(en)
*
|
2003-05-22 |
2011-04-26 |
Elan Pharma International Ltd. |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
EP1648948B1
(en)
*
|
2003-07-18 |
2012-02-08 |
Agency for Science, Technology and Research |
Thermosensitive polymers for therapeutic use and methods of preparation
|
DE602004018150D1
(de)
*
|
2003-08-08 |
2009-01-15 |
Elan Pharma Int Ltd |
Neue metaxalon-zusammensetzungen
|
ES2366646T3
(es)
*
|
2003-11-05 |
2011-10-24 |
Elan Pharma International Limited |
Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
|
US20080249076A1
(en)
*
|
2003-12-03 |
2008-10-09 |
Lifecycle Pharma A/S |
Pharmaceutical Compositions Comprising Danazol
|
US20090004277A1
(en)
*
|
2004-05-18 |
2009-01-01 |
Franchini Miriam K |
Nanoparticle dispersion containing lactam compound
|
EP2623095A1
(en)
*
|
2004-11-16 |
2013-08-07 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
US20090155331A1
(en)
*
|
2005-11-16 |
2009-06-18 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
UA89513C2
(uk)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Стабільна композиція з наночастинок ралоксифену гідрохлориду
|
WO2006066063A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Elan Pharma International Ltd. |
Nanoparticulate tacrolimus formulations
|
WO2006069098A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Elan Pharma International Ltd. |
Nanoparticulate bicalutamide formulations
|
BRPI0606434A2
(pt)
*
|
2005-01-06 |
2009-06-30 |
Elan Pharma Int Ltd |
formulações de candesartana nanoparticulada
|
AU2006214443C1
(en)
|
2005-02-15 |
2011-11-24 |
Alkermes Pharma Ireland Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
US20060204588A1
(en)
*
|
2005-03-10 |
2006-09-14 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
|
MX2007011502A
(es)
*
|
2005-03-16 |
2007-12-07 |
Elan Pharma Int Ltd |
Formulaciones de antagonista del receptor de leucotrieno en nanoparticulas con corticosteroide.
|
NZ561666A
(en)
|
2005-03-17 |
2010-05-28 |
Elan Pharma Int Ltd |
Nanoparticulate biphosphonate compositions
|
KR20070121786A
(ko)
*
|
2005-03-23 |
2007-12-27 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 코르티코스테로이드 및 항히스타민 제제
|
WO2006110802A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cyclosporine
|
BRPI0607537A2
(pt)
*
|
2005-04-12 |
2009-09-15 |
Elan Pharma Int Ltd |
formulações de derivado de quinazolina nanoparticulado
|
US20060246141A1
(en)
*
|
2005-04-12 |
2006-11-02 |
Elan Pharma International, Limited |
Nanoparticulate lipase inhibitor formulations
|
EP1954253A4
(en)
|
2005-06-08 |
2011-07-27 |
Elan Pharma Int Ltd |
NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
|
AU2006269961B2
(en)
*
|
2005-07-15 |
2012-07-19 |
Map Pharmaceuticals, Inc. |
Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
RU2009102262A
(ru)
*
|
2006-06-26 |
2010-08-10 |
Мьючуал Фармасьютикал Компани, Инк. (Us) |
Композиции активного агента, способы их получения и способы применения
|
WO2008024703A1
(en)
*
|
2006-08-23 |
2008-02-28 |
Dow Global Technologies Inc. |
Aqueous compositions
|
CL2007002689A1
(es)
|
2006-09-18 |
2008-04-18 |
Vitae Pharmaceuticals Inc |
Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
BRPI0811681A2
(pt)
*
|
2007-06-21 |
2014-09-30 |
Dow Global Technologies Inc |
"composição para cuidados pessoais e método para estabilizar um componente hidrofóbico"
|
US8642062B2
(en)
|
2007-10-31 |
2014-02-04 |
Abbott Cardiovascular Systems Inc. |
Implantable device having a slow dissolving polymer
|
US20090238867A1
(en)
*
|
2007-12-13 |
2009-09-24 |
Scott Jenkins |
Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
US20100159010A1
(en)
*
|
2008-12-24 |
2010-06-24 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
DK3045043T3
(da)
|
2009-02-26 |
2020-08-03 |
Relmada Therapeutics Inc |
Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
|
US7828996B1
(en)
|
2009-03-27 |
2010-11-09 |
Abbott Cardiovascular Systems Inc. |
Method for the manufacture of stable, nano-sized particles
|
US20100291221A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Robert Owen Cook |
Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
CA2763456C
(en)
|
2009-05-27 |
2017-10-24 |
Alkermes Pharma Ireland Limited |
Reduction of flake-like aggregation in nanoparticulate active agent compositions
|
US8309489B2
(en)
*
|
2009-06-18 |
2012-11-13 |
University Of Central Florida Research Foundation, Inc. |
Thermally stable nanoparticles on supports
|
AR077692A1
(es)
|
2009-08-06 |
2011-09-14 |
Vitae Pharmaceuticals Inc |
Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
|
US9012511B2
(en)
|
2010-05-19 |
2015-04-21 |
Alkermes Pharma Ireland Limited |
Nanoparticulate cinacalcet compositions
|
JP6096670B2
(ja)
*
|
2010-12-10 |
2017-03-15 |
ビーエーエスエフ ソシエタス・ヨーロピアBasf Se |
酸化ケイ素誘電体膜およびポリシリコン膜を含有する基板を化学的機械的に研磨するための水性研磨組成物および方法
|
GB201111438D0
(en)
*
|
2011-07-04 |
2011-08-17 |
Syngenta Ltd |
Formulation
|
GB201111439D0
(en)
*
|
2011-07-04 |
2011-08-17 |
Syngenta Ltd |
Formulation
|
EP2734204A4
(en)
|
2011-07-22 |
2015-03-18 |
Chemocentryx Inc |
POLYMORPHIC FORMS OF 4-TERT-BUTYL-N- [4-CHLORO-2- (1-OXY-PYRIDINE-4-CARBONYL) -PHENYL] -BENZENE-SULFONAMIDE SODIUM SALT
|
JP6122003B2
(ja)
|
2011-07-22 |
2017-04-26 |
ケモセントリックス, インコーポレイテッド |
4−tert−ブチル−N−[4−クロロ−2−(1−オキシ−ピリジン−4−カルボニル)−フェニル]−ベンゼンスルホンアミドのナトリウム塩の結晶形
|
EA027972B1
(ru)
|
2011-09-01 |
2017-09-29 |
Глэксо Груп Лимитед |
Новая кристаллическая форма
|
PT3160958T
(pt)
|
2014-06-25 |
2021-04-07 |
Glaxosmithkline Ip Dev Ltd |
Sais cristalinos de (s)-6-((1-acetilpiperidin-4-il)amino)- n-(3-(3,4-di-hidroisoquinolin-2(1h)-il)-2- hidroxipropil)pirimidina-4-carboxamida
|
JP2017527574A
(ja)
|
2014-09-08 |
2017-09-21 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
2−(4−(4−エトキシ−6−オキソ−1,6−ジヒドロピリジン−3−イル)−2−フルオロフェニル)−n−(5−(1,1,1−トリフルオロ−2−メチルプロパン−2−イル)イソオキサゾール−3−イル)アセトアミドの結晶形
|
CN107709344B
(zh)
|
2015-05-01 |
2022-07-15 |
共晶制药股份有限公司 |
用于治疗黄病毒科病毒和癌症的核苷类似物
|
CA3159382A1
(en)
|
2019-11-01 |
2021-05-06 |
Aquestive Therapeutics, Inc. |
Prodrug compositions and methods of treatment
|
KR20220126287A
(ko)
|
2019-11-14 |
2022-09-15 |
어퀘스티브 테라퓨틱스, 아이엔씨. |
멀티모달 조성물 및 치료 방법
|
CN116940351A
(zh)
|
2021-01-15 |
2023-10-24 |
阿奎斯蒂弗医疗股份有限公司 |
前药组合物和治疗方法
|